real-time news and commentary for investors
Monday, Nov 26
2012, 8:29 AM
Valeant's (VRX) efinaconazole antifungal cream for treating onychomycosis, a common nail...
Valeant's (VRX) efinaconazole antifungal cream for treating onychomycosis, a common nail infection that affects 10% of Americans, performed well in two Phase III trials. In Study 1, efinaconazole totally cured 17.8% of patients vs 3.3% with the placebo, and in Study II, the drug cured 15.2% vs 5.5%. The results suggest that efinaconazole could become the first alternative treatment to risky oral medicines. (PR)